Milrinone Wockhardt Uk (Milrinone)

Milrinone works by selectively inhibiting the enzyme phosphodiesterase‑3, which raises intracellular cyclic AMP levels in cardiac and vascular smooth‑muscle cells. The increase in cAMP enhances calcium entry during heart muscle contraction, producing a positive inotropic effect, while also causing vasodilation that reduces afterload.

The dosing regimen for Milrinone is individualized by the prescribing clinician based on the patient’s clinical status, weight, and response. The prescriber determines the loading dose, infusion rate, and duration according to approved guidelines and institutional protocols.

Milrinone is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used during pregnancy only if the potential benefit justifies any potential risk to the fetus. Limited data are available for breastfeeding, so caution is advised.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Milrinone Wockhardt Uk. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Milrinone differs from catecholamine inotropes such as dobutamine by acting through phosphodiesterase‑3 inhibition rather than beta‑adrenergic stimulation. This mechanism provides both inotropic support and vasodilation, which can be advantageous in patients with high systemic vascular resistance, but it may also increase the risk of hypotension compared with agents that lack vasodilatory activity.

Milrinone injectable solution should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Once removed from refrigeration, use the solution within the time frame specified by the manufacturer.

Milrinone is given by intravenous infusion. After reconstitution according to the label instructions, the solution is administered through a controlled infusion pump, typically starting with a loading dose followed by a maintenance infusion. Continuous hemodynamic monitoring is recommended during administration.

The most serious adverse events associated with Milrinone include severe hypotension, life‑threatening ventricular arrhythmias (such as torsades de pointes), myocardial ischemia, and anaphylactic reactions. Prompt recognition and management of these events are essential, and patients should be monitored closely throughout therapy.

Milrinone is contraindicated in patients with known hypersensitivity to the drug, severe aortic stenosis, uncontrolled ventricular arrhythmias, or those who are hemodynamically unstable due to profound hypotension. Caution is also advised in patients with recent myocardial infarction or significant electrolyte abnormalities.